AbbVie has announced a landmark $10.9 billion acquisition of Apogee Therapeutics, a strategic move poised to significantly fortify the biopharmaceutical…
Read More
Biogen Acquires RayThera for Up to $1 Billion to Bolster Immunology Pipeline
Biogen Inc. has announced a definitive agreement to acquire RayThera, a privately held biotechnology company focused on developing small-molecule therapies…
Read More
Biopharma M&A Surges as Billion-Dollar Deals Fuel Pipeline Replenishment Amidst Patent Cliff Pressures
The biopharmaceutical industry is experiencing a significant resurgence in merger and acquisition (M&A) activity, driven by a wave of high-value…
Read More
Europe Must Rethink Funding and De-Risk Assets to Secure its Rare Disease Research Pipeline
The 13th European Conference on Rare Diseases and Orphan Products, held in Prague, Czech Republic, from June 3-4, 2026, served…
Read More
Parabilis Medicines Aims for $475 Million Nasdaq IPO to Fund Pivotal Desmoid Tumour Trial and Pipeline Expansion
Parabilis Medicines, a biopharmaceutical company forging innovative therapeutic pathways, is charting a course for public market debut with a proposed…
Read More
Pfizer and Innovent Biologics Announce Landmark Global Collaboration for Oncology Pipeline, Valued Up to $10.5 Billion
In a significant move poised to accelerate the development of novel cancer treatments, global pharmaceutical giant Pfizer and leading Chinese…
Read More
Immunai’s Digital "Plumbing" Secures Third Expansion with AstraZeneca, Deepening AI Integration Across Clinical Pipeline
Immunai, a pioneering startup dedicated to constructing a foundational model of the human immune system, has announced its third significant…
Read More
The Hereditary Angioedema Pharmaceutical Landscape Poised for Unprecedented Expansion Driven by Late-Stage Pipeline and Emerging Technologies
The pharmaceutical landscape for hereditary angioedema (HAE) is on the cusp of a significant transformation, marked by an unprecedented surge…
Read More
Gilead Sciences Finalizes $5 Billion Acquisition of Tubulis, Bolstering Oncology Pipeline with Advanced ADC Technology
Gilead Sciences has officially completed its acquisition of Tubulis, a prominent German biotechnology firm specializing in the development of next-generation…
Read More
Eli Lilly Acquires Engage Biologics for Up to $202 Million, Bolstering Its Genetic Medicine Pipeline with Innovative Non-Viral DNA Delivery Technology
Pharmaceutical giant Eli Lilly and Company has announced its agreement to acquire Engage Biologics, a California-based biotechnology firm, for a…
Read More
